GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Cash-to-Debt

iSpecimen (iSpecimen) Cash-to-Debt : 25.54 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. iSpecimen's cash to debt ratio for the quarter that ended in Dec. 2023 was 25.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, iSpecimen could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for iSpecimen's Cash-to-Debt or its related term are showing as below:

ISPC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 4.13   Max: 82.75
Current: 25.54

During the past 6 years, iSpecimen's highest Cash to Debt Ratio was 82.75. The lowest was 0.01. And the median was 4.13.

ISPC's Cash-to-Debt is ranked better than
86.32% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.39 vs ISPC: 25.54

iSpecimen Cash-to-Debt Historical Data

The historical data trend for iSpecimen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

iSpecimen Cash-to-Debt Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial 0.01 0.06 8.10 82.75 25.54

iSpecimen Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.75 74.98 76.06 24.20 25.54

Competitive Comparison of iSpecimen's Cash-to-Debt

For the Diagnostics & Research subindustry, iSpecimen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where iSpecimen's Cash-to-Debt falls into.



iSpecimen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

iSpecimen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

iSpecimen's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iSpecimen  (NAS:ISPC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


iSpecimen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of iSpecimen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen (iSpecimen) Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420